Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Montag A & Associates Inc.

Montag A & Associates Inc. grew its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 9.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 20,999 shares of the biopharmaceutical company’s stock after acquiring an additional 1,758 shares during the period. Montag A & Associates Inc.’s holdings in Bristol-Myers Squibb were worth $1,139,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Northwest Financial Advisors acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $27,000. Accordant Advisory Group Inc acquired a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $31,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $34,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $40,000. Finally, Wetzel Investment Advisors Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at approximately $40,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded down $0.32 during mid-day trading on Monday, hitting $40.14. The company had a trading volume of 6,569,477 shares, compared to its average volume of 15,620,978. The stock has a market cap of $81.37 billion, a price-to-earnings ratio of -12.92, a PEG ratio of 14.05 and a beta of 0.44. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $65.38. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The firm’s 50 day simple moving average is $41.92 and its two-hundred day simple moving average is $47.33.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same quarter in the previous year, the firm posted $2.05 EPS. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 dividend on an annualized basis and a yield of 5.98%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. BMO Capital Markets lowered their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. Barclays lowered their price objective on Bristol-Myers Squibb from $43.00 to $41.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 10th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday, April 18th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 27th. Finally, William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $59.07.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.